Naltrexone was associated with improvement in BPD in a dose-dependent manner. The study provided additional evidence that dysregulation of the endogenous opioid system is implicated in the pathophysiology of BPD symptoms.

Hum Psychopharmacol. 2021 Nov;36(6)

Efficacy of naltrexone in borderline personality disorder, a retrospective analysis in inpatients

Click here to access the PubMed abstract of this article.

LDN showed some benefit for major depressive disorder relapse on pro-dopaminergic antidepressant regimens. Larger studies are needed.

J Affect Disord. 2017 Jan 15;208:6-14.

Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants

Click here to access the PubMed abstract of this article.

Treatment with low-dose naltrexone may be a helpful element in the treatment of patients with complex posttraumatic stress disorder. However, it must be realized that the decrease of dissociation may lead patients to a not yet resolvable challenge, in as much as dissociation had previously been a necessary mechanism of self-protection.

Nervenarzt. 2015 Mar;86(3):346-51. (article in German)

[Low dose naltrexone in the treatment of dissociative symptoms]

Click here to access the PubMed abstract of this article.

Accumulating evidence suggests that Low Dose Naltrexone can promote health-supporting immune-modulation which may reduce various oncogenic and inflammatory autoimmune processes. LDN may also play a role in healing and repair of tissues, as well as promoting stress resilience, exercise, social bonding, and emotional well-being, and ameliorating psychiatric problems such as autism and depression.

Med Hypotheses. 2009 Mar;72(3):333-7.

Low-dose naltrexone for disease prevention and quality of life.

Click here to access the PubMed abstract of this article.